HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results
HCW Biologics Inc., a clinical-stage biopharmaceutical company listed on NASDAQ, reported first quarter 2026 results highlighting progress in its Phase 1 trial for HCW9302 targeting alopecia areata, completion of an exclusive worldwide license agreement with Trimmune Biotech, and financial improvements including a net income of $3.5 million. The co…